Steven Gavel - Legend BiotechCorp US Development
| LEGN Stock | USD 51.71 1.21 2.29% |
Executive
Steven Gavel is US Development of Legend BiotechCorp
| Address | 2101 Cottontail Lane, Somerset, NJ, United States, 08873 |
| Phone | 732 317 5050 |
| Web | https://www.legendbiotech.com |
Legend BiotechCorp Management Efficiency
The company has return on total asset (ROA) of (0.1739) % which means that it has lost $0.1739 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5194) %, meaning that it created substantial loss on money invested by shareholders. Legend BiotechCorp's management efficiency ratios could be used to measure how well Legend BiotechCorp manages its routine affairs as well as how well it operates its assets and liabilities. As of the 16th of April 2024, Return On Tangible Assets is likely to drop to -0.32. In addition to that, Return On Capital Employed is likely to drop to -0.28. At this time, Legend BiotechCorp's Net Tangible Assets are very stable compared to the past year. As of the 16th of April 2024, Intangible Assets is likely to grow to about 163 M, while Total Assets are likely to drop about 938.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Lucia Celona | Apellis Pharmaceuticals | 51 | |
| Alex Howarth | Madrigal Pharmaceuticals | 55 | |
| Kathryn Haviland | Blueprint Medicines Corp | 48 | |
| Janet Graesser | VaxcyteInc | N/A | |
| Thomas Hare | Madrigal Pharmaceuticals | N/A | |
| Evan Lippman | Alnylam Pharmaceuticals | N/A | |
| MS JD | Arcellx | N/A | |
| Pushkal MD | Alnylam Pharmaceuticals | 56 | |
| Kristin Hodous | Blueprint Medicines Corp | N/A | |
| Keith White | Amylyx Pharmaceuticals | N/A | |
| Ronald Filippo | Madrigal Pharmaceuticals | N/A | |
| Saraswathy Nochur | Alnylam Pharmaceuticals | 63 | |
| Evan MBA | Alnylam Pharmaceuticals | N/A | |
| Tina Ventura | Madrigal Pharmaceuticals | N/A | |
| Paul Shin | 89bio Inc | N/A | |
| Steven Axon | Apellis Pharmaceuticals | N/A | |
| Shiva CPA | 89bio Inc | 58 | |
| Yajing Chen | Zai Lab | N/A | |
| Casey Logan | Travere Therapeutics | N/A | |
| Shiva Natarajan | 89bio Inc | 58 | |
| Nyssa Noyola | Ascendis Pharma AS | N/A | |
Management Performance
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.17 |
Legend BiotechCorp Leadership Team
Elected by the shareholders, the Legend BiotechCorp's board of directors comprises two types of representatives: Legend BiotechCorp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Legend. The board's role is to monitor Legend BiotechCorp's management team and ensure that shareholders' interests are well served. Legend BiotechCorp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Legend BiotechCorp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James JD, General Counsel | ||
| Lori CPA, Chief Officer | ||
| Guowei Fang, Chief Development | ||
| Elaine Qian, VP Resources | ||
| Tina Carter, Corporate Lead | ||
| Steven Gavel, US Development | ||
| Marc Harrison, VP Counsel | ||
| Liz Gosen, Senior Operations | ||
| Surabhi Verma, Manager Communications | ||
| Ying Huang, CEO Director | ||
| Yuhong Qiu, Senior Affairs | ||
| Doug Wallace, Vice Operations | ||
| Alan Kick, Senior Quality | ||
| Joanne Choi, Senior Relations | ||
| Deborah Wong, Executive Communications |
Legend Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Legend BiotechCorp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (1.82) % | ||||
| Operating Margin | (1.52) % | ||||
| Current Valuation | 18.27 B | ||||
| Shares Outstanding | 181.91 M | ||||
| Shares Owned By Insiders | 1.30 % | ||||
| Shares Owned By Institutions | 48.71 % | ||||
| Number Of Shares Shorted | 9.99 M | ||||
| Price To Book | 7.69 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend BiotechCorp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Legend Stock, please use our How to Invest in Legend BiotechCorp guide.Note that the Legend BiotechCorp information on this page should be used as a complementary analysis to other Legend BiotechCorp's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Legend Stock analysis
When running Legend BiotechCorp's price analysis, check to measure Legend BiotechCorp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Legend BiotechCorp is operating at the current time. Most of Legend BiotechCorp's value examination focuses on studying past and present price action to predict the probability of Legend BiotechCorp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Legend BiotechCorp's price. Additionally, you may evaluate how the addition of Legend BiotechCorp to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is Legend BiotechCorp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Legend BiotechCorp. If investors know Legend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Legend BiotechCorp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.94) | Revenue Per Share 1.619 | Quarterly Revenue Growth 1.876 | Return On Assets (0.17) | Return On Equity (0.52) |
The market value of Legend BiotechCorp is measured differently than its book value, which is the value of Legend that is recorded on the company's balance sheet. Investors also form their own opinion of Legend BiotechCorp's value that differs from its market value or its book value, called intrinsic value, which is Legend BiotechCorp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Legend BiotechCorp's market value can be influenced by many factors that don't directly affect Legend BiotechCorp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Legend BiotechCorp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Legend BiotechCorp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Legend BiotechCorp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.